Literature DB >> 9371366

Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients.

K Hultén1, A Gibreel, O Sköld, L Engstrand.   

Abstract

Helicobacter pylori strains from seven patients treated with clarithromycin were investigated for development, mechanism, and stability of resistance. Genetic relatedness between pre- and posttreatment isolates was shown by arbitrary primed PCR. Clarithromycin resistance was associated with A-to-G transitions at either position 2143 or 2144 or at both positions 2116 and 2142. In four cases, the mutations were homozygous. The Cla(r) phenotype was stable after 50 subcultivations in vitro. No erythromycin-modifying enzymes or rRNA methylases were found by biological assays, PCR and sequencing, or cloning methods.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9371366      PMCID： PMC164161     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase.

Authors:  F Sanger; A R Coulson
Journal:  J Mol Biol       Date:  1975-05-25       Impact factor: 5.469

2.  Detection of erythromycin resistance by the polymerase chain reaction using primers in conserved regions of erm rRNA methylase genes.

Authors:  M Arthur; C Molinas; C Mabilat; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Nucleotide sequence of ermA, a macrolide-lincosamide-streptogramin B determinant in Staphylococcus aureus.

Authors:  E Murphy
Journal:  J Bacteriol       Date:  1985-05       Impact factor: 3.490

4.  Cloning and analysis of ermG, a new macrolide-lincosamide-streptogramin B resistance element from Bacillus sphaericus.

Authors:  M Monod; S Mohan; D Dubnau
Journal:  J Bacteriol       Date:  1987-01       Impact factor: 3.490

5.  Plasmid-mediated high-level resistance to erythromycin in Escherichia coli.

Authors:  A Andremont; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

6.  Characterization of plasmids and plasmid-borne macrolide resistance from Lactobacillus sp. strain 100-33.

Authors:  L A Rinckel; D C Savage
Journal:  Plasmid       Date:  1990-03       Impact factor: 3.466

7.  Cloning and hybridization analysis of ermP, a macrolide-lincosamide-streptogramin B resistance determinant from Clostridium perfringens.

Authors:  D I Berryman; J I Rood
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Characterization of erythromycin resistance in Campylobacter jejuni and Campylobacter coli.

Authors:  W Yan; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

9.  PCR-based RFLP analysis of DNA sequence diversity in the gastric pathogen Helicobacter pylori.

Authors:  N Akopyanz; N O Bukanov; T U Westblom; D E Berg
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

10.  Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers.

Authors:  B H Jaup; A Norrby
Journal:  Am J Gastroenterol       Date:  1995-06       Impact factor: 10.864
View more
  54 in total

1.  Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium.

Authors:  M Matsumura; Y Hikiba; K Ogura; G Togo; I Tsukuda; K Ushikawa; Y Shiratori; M Omata
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 2.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

3.  PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates.

Authors:  T Alarcón; D Domingo; N Prieto; M López-Brea
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

6.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin.

Authors:  Armelle Ménard; Adriana Santos; Francis Mégraud; Mónica Oleastro
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects.

Authors:  Paolo Scarpellini; Paola Carrera; Annalisa Cavallero; Massimo Cernuschi; Gianni Mezzi; Pier Alberto Testoni; Anna Zingale; Adriano Lazzarin
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 9.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

10.  T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh.

Authors:  Rasel Khan; Shamsun Nahar; Jinath Sultana; Mian Mashhud Ahmad; Motiur Rahman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.